Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03412760 · ClinicalTrials.gov registry record · NA
Hydrops: Diagnosing & Redefining Outcomes With Precision Study
A NA study of Birth Defect and Fetal Anomaly, sponsored by University of California, San Francisco.
- Active
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT03412760: Active NA study of Birth Defect and Fetal Anomaly, sponsored by University of California, San Francisco.
NCT03412760 is a NA study of Birth Defect and Fetal Anomaly that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 500 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03412760, a NA study of Birth Defect and Fetal Anomaly, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a national, prospective study designed to investigate the genetic etiologies of non-immune hydrops fetalis (NIHF) and other birth defects. At least half of prenatally diagnosed NIHF cases remain of unknown etiology after standard work up, and a substantial proportion of other birth defects remain of unknown etiology as well. The investigators are performing exome sequencing (ES) for the affected fetus or neonate in unexplained cases, as well as enrolling cases with a genetic explanation to represent the full spectrum of diseases underlying NIHF and other birth defects.
Primary Outcome
Both NIHF and birth defects can be caused by a variety of genetic variants that researchers are continuing to learn more about. Exome sequencing will yield information about the specific genetic variants present in cases of NIHF and other birth defects, and about the specific diseases implicated by these variants. Investigators will determine the proportion of cases seen in the setting of particular genetic variants, and will correlate phenotypic outcomes with specific genotypes.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Exome sequencing
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2027-02 |
| Phase | NA |
What the registry record for NCT03412760 still lists
NCT03412760 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 3 conditions, with Birth Defect appearing as the primary indexed condition, and to 1 intervention - of which Exome sequencing is the first listed.
NCT03412760 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03412760 about?
NCT03412760 is a clinical study titled "Hydrops: Diagnosing & Redefining Outcomes With Precision Study". This is a national, prospective study designed to investigate the genetic etiologies of non-immune hydrops fetalis (NIHF) and other birth defects. At least half of prenatally diagnosed NIHF cases remain of unknown etiology after standard work up, and a substantial proportion of other birth defects r...
What is the current status of trial NCT03412760?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2018-10-11. Estimated completion is 2027-02.
What conditions does trial NCT03412760 study?
This clinical trial studies the following conditions: Birth Defect, Fetal Anomaly, Hydrops Fetalis.
What interventions are being tested in trial NCT03412760?
The interventions under investigation include: Exome sequencing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03412760?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03412760 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Birth Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03412760's enrollment target sits among peer trials
500 193rd of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI